Small Intestinal Bacterial Overgrowth
1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BiocorpCapScan collection capsule
Atmo BiosciencesAtmo Gas Capsule
Atmo BiosciencesAtmo Gas Capsule
Clinical Trials (3)
Total enrollment: 197 patients across 3 trials
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
Start: Feb 2024Est. completion: Feb 202634 patients
Phase 1Recruiting
Atmo SmartPill Comparison in Gastroparetic and Slow Transit Constipation Patients
Start: Aug 2021Est. completion: Mar 202353 patients
N/ACompleted
Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
Start: Jul 2021Est. completion: Aug 2025110 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 197 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.